A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer
Clinical trial NCT04924699 · UNKNOWN
Trial details
- NCT number
- NCT04924699
- Sponsor
- Shanghai Miracogen Inc.
- Status
- UNKNOWN
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-06-30
- Primary completion
- 2023-09-01
- Enrollment
- 350
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.